This October, three (3) plant patent applications (US Patent Pub. Nos. 20200329599, ‘600, & ‘601) filed by GenCann, LLC inventors were published for three cannabis cultivars, “V1,” “V2,” and “V3” which contain a higher amount of tetrahydrocannabivarin (THCV) by weight than tetrahydrocannabinol (THC) as well as a unique terpene, farnesene.
THCV has shown great therapeutic potential in mice. It can decrease appetite, increase satiety, and up-regulate energy metabolism, making it a potential candidate for weight loss treatments and diabetes management (Abioye et al., 2020). Likewise, farnesene exhibits excellent therapeutic benefits such as anti-inflammation qualities and potentially tumor-inhibition.
Cannabis cultivar plant patents have been filed for as early as June of 2017, with the first coming from Green Brands, LLC. However, the cannabis cultivar space has come to be dominated by Biotech Institute LLC, and more recently, GenCann.
GenCann filed three (3) utility patent applications (US Patent. Pub. Nos. 20200323162, ‘163, ‘164) for the cultivars ‘V1,’ ‘V2,’ and ‘V3’ several months after filing for the plant patents. Others in the space, including famed Charlotte’s Web, have also taken to filing utility patents for cannabis plants. Explore the quickly developing Cannabis sector through Magic Number’s Cannabis Patent Forecast® which analyzes and highlights patent and market data. Try it free for one week here!
